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Abstract 
A 63-year-old accountant developed progressive somnolence, cognitive decline, gait disturbance 
and cerebellar dysfunction with autonomic features. This report documents the 
clinicopathological conference at the 39th Edinburgh Advanced Neurology Course 2017. 
 
History 
 
A 63-year-old right-handed accountant became unwell in summer 2013, with abdominal 
symptoms, somnolence, unsteadiness and weight loss of two stones. He had stopped driving due 
to safety concerns; he had become withdrawn, lost enjoyment playing guitar, had reduced libido 
and had become reluctant to leave the house. He was taking omeprazole and fluoxetine. He had 
previously undergone mastoid surgery. He lived with his wife and daughter, had never smoked 
and drank little alcohol. He had completed a 400-mile bike trip in India in 2011 (Figure 1A). His 
mother and maternal grandmother had dementia in their 80s. Initial examination showed square 
wave jerks, unsteady gait and finger-nose ataxia, worse on the left. An Addenbrooke’s Cognitive 
Examination-Revised (ACE-R) score was 99/100. 
 
He was diagnosed with sleep apnoea, and initially responded well to continuous positive airway 
pressure (CPAP), but by mid-2015 was sleeping up to 20 hours/day. His unsteadiness 
progressed, he developed generalised itch and became apathetic. He made inappropriate jokes, 
and lost empathy. He developed anxiety and a marked fear of heights, urinary hesitancy and 
erectile dysfunction, and struggled to operate the TV remote control. He suffered from acid reflux 
and diarrhoea. 
 
On examination (in July 2015), there were bilateral palmomental, snout and pout reflexes, jerky 
saccades with nystagmus and slurred speech. There was no bradykinesia, but he showed a 
staring appearance. Tone and muscle strength were normal, and his gait was broad based. There 
was difficulty with praxis and sequencing. His plantar flexors and tendon reflexes were normal. 
His investigations were unremarkable (Box1), except for atrophy on MR scan of brain, and 
cerebrospinal fluid (CSF) showed 7x10^9/L white cells and unmatched oligoclonal bands (see 
results). Prednisolone 40 mg for 1 month gave no benefit. By March 2016, he was using a 
wheelchair. His ACE-R was 69/100 (attention 16/18, memory 16/26, fluency 3/14, language 
23/26, visuospatial 7/16). He had reduced facial expression, increased tone in all limbs and 
prominent cerebellar signs. In April 2016, he was admitted to hospital after a fall, discharged to a 
nursing home (Figure 1B) and, by October 2016, he was bed bound. He died in November 2016 
aged 66 years. 
 
 
Box 1  
Investigations 
Blood 
 Full blood count, erythrocyte sedimentation rate, plasma glucose, liver function tests, 
thyroid function tests, serum urea, electrolytes, creatinine and creatine kinase were all 
normal. 
 Vitamin E 5.3 μmol/mmol (normal). 
 Serum lipids and triglycerides were normal. 
 Antibodies to voltage-gated potassium channels, voltage-gated calcium channels, glutamic 
acid decarboxylase, islet antigen-2, N-methyl-D-aspartate (NMDA), thyroperoxidase, 
acetylcholine receptors, Yo, Hu and Ri, tissue transglutaminase IgA were all negative. 
 Extractable nuclear antigens, antinuclear antibodies, anti-cyclic citrullinated peptide were 
negative. 
 HIV and antitreponemal IgG were negative. 
 Ataxia genetics: SCA1, SCA2, SCA3, SCA6, SCA7, FRDA and FXTA genes were all negative. 
 Neurodegenerative gene panel: C9Orf72 5–10 repeats (normal) both alleles, APP, CHMP2B, 
FUS, GRN, LRRK2, MAPT, PARK2, PSEN1, PSEN2, SOD1, SQSTM1, TARDBP, UBQLN2, VAPB, 
VCP sequences were all normal. 
CSF 
 March 2014: white cell count 6x10^9/L; red cell count 0x10^12/L; CSF glucose 3.3 (serum 
4.1), protein 0.31 g/L; multiple unpaired IgG oligoclonal bands in CSF. 
 September 2015: white cell count 7x10^9/L; red cell count 0x10^12/L; CSF glucose 3.7 
(serum 4.5), protein 0.33 g/L; multiple unpaired oligoclonal bands in CSF; tau 111, β-amyloid 
104 (normal), Whipple’s PCR negative; CSF microscopy no organisms seen; enterovirus, HSV1 
PCR, HSV2 PCR, parechovirus PCR, varicella zoster PCR all negative; CSF cytology (4 mL) no 
significant cellular component, no evidence of malignancy or inflammation. 
Imaging 
 March 2014: MR scan of brain showed generalised atrophy, advanced for age, no other 
abnormalities. 
 January 2015: MR scan of brain (unenhanced) showed moderate global cerebral atrophy, 
advanced for age, unchanged from 2014. Mild chronic microvascular changes also 
accelerated for age. No other abnormalities. 
 June 2014: dopamine transporter scan (DaTSCAN) was normal. 
 September 2015: CT scan of chest/abdomen/pelvis with contrast was unremarkable. 
EEG 
 2015: bursts of generalised slow with some intermixed sharp waves; in keeping with cerebral 
dysfunction but not specific. 
Sleep study 
 May 2014: 55 apnoeas/hypopnoeas per hour. 
Colonoscopy 
 Two polyps removed from proximal ascending colon: tubular adenoma showing low-grade 
dysplasia. Pedunculated polyp in splenic flexure: tubular adenoma, no sign of invasion. Two 
biopsies of right and left colon: normal. 
Upper GI endoscopy 
 Prepyloric biopsies: chemical gastritis; duodenal D2 biopsies: mild duodenitis. 
 APP, amyloid precursor protein; CHMP2B, charged multivesicular body protein 2B; CSF, 
cerebrospinal fluid; EEG, electroencephalogram; FRDA, Friedreich ataxia; FUS, fused in 
sarcoma; FXTA, fragile X tremor associated; GI, gastrointestinal; GRN, progranulin gene; HSV, 
herpes simplex virus; LRRK2, leucine-rich repeat kinase 2; MAPT, microtubule-associated 
protein tau; PARK2, gene-encoding Parkin; PSEN, gene-encoding presenilin; SCA, 
spinocerebellar ataxia; SOD1, superoxide dismutase 1; SQSTM1, gene-encoding 
sequestosome 1; TARDBP, gene for TDP-43 (Tar-binding protein 43); UBQLN2, gene for 
ubiquilin-2; VAPB, gene for vesicle-associated membrane protein B/C; VCP, valosin-
containing protein. 
 
 
 
 
Discussant: Professor Jonathon Schott 
 
The received wisdom in medicine—and neurology in particular—is that diagnosis is almost 
always made from the history. Evidence comes from a study that looked at outpatient clinics 
across a spectrum of disciplines, including neurology, and determined the contribution that the 
history, examination and investigations made to the final diagnosis. History accounted for 82% of 
diagnoses, 9% came from the examination and investigations helped in 9% (1).  In a CPC, the 
investigation findings are unlikely to give the answer, and so reviewing the history is even more 
important. 
 
The history… 
 
He is an educated man, important when it comes to assessing cognition. He takes omeprazole and 
fluoxetine, both commonly prescribed drugs but potentially relevant if gastrointestinal 
symptoms or depression are part of his neurological illness. He has vague abdominal symptoms, 
which hint at an autonomic problem. He completed a bike trip in India in 2011, meaning balance 
and planning skills were good then, but might he have been exposed to infection? His mother 
developed dementia in late life, not unusual and unlikely to be relevant. 
 
A prominent early feature was daytime somnolence. He was struggling with work, which may 
reflect sleepiness, depression or cognitive problems. He was diagnosed with obstructive sleep 
apnoea and initially responded well to CPAP. However, the degree of his somnolence—sleeping 
20 hours/day—and the subsequent course make it clear this is not just sleep apnoea. 
One year into his illness he is unsteady, which could reflect vestibular dysfunction, neuropathy or 
pyramidal weakness, but he has a broad-based unsteady gait, square wave jerks, with minimal 
finger-nose ataxia, suggesting an axial cerebellar problem. Importantly, he is not parkinsonian. 
He has poor spatial awareness but it is not clear whether this is due to a visuospatial problem 
(right parietal dysfunction), sleepiness or executive dysfunction. He has lost two stones in 
weight, which might reflect a systemic illness or autonomic dysfunction. 
 
He becomes apathetic, likely reflecting decline in executive function. He has difficulty using the 
TV remote control, which may reflect dyspraxia (left parietal dysfunction), visuospatial (right 
parietal lobe) or executive problems. Neuropsychiatric features also emerge (anxiety). 
He develops itch, which is most often due to diseases such as eczema or psoriasis, but can suggest 
systemic disorders including lymphoma and leukaemia. There are neurological causes for 
‘central’ itch, including anti-aquaporin-4 syndromes. His itch is worse at night, commonly the 
case because of a lack of distraction, but with sleep disturbance raises the possibility of a primary 
parasomnia (2).  Latterly, he develops clear autonomic disturbance, with urinary hesitancy, 
erectile dysfunction, reflux and loose stools. 
 
…and the examination 
 
The palmomental reflex is not a useful diagnostic sign (3).  He has a snout reflex, a frontal release 
sign. Tone, power and reflexes are normal, but he has a pout reflex, an upper motor neurone sign. 
He has jerky saccades with nystagmus, localising pathology to the cerebellum, brainstem or 
connections; there is slurring of speech suggesting the former. Despite a staring appearance he is 
not bradykinetic, that is, he does not have true parkinsonism. He has difficulty with praxis, 
consistent with left parietal dysfunction. 
 
Three years later he is a wheelchair user, hypomimic, with increased tone throughout. He has 
marked cerebellar signs and memory problems. We must exercise caution when considering 
memory as a localising feature in the context of excessive sleepiness and dysexecutive function 
where it is difficult to maintain concentration. The breakdown of his ACE-R score reveals that 
fluency is very affected (a frontal/executive feature) as is visuospatial functioning, while 
language and attention are relatively spared. His memory is impaired although not as much as 
other domains. This pattern can therefore best be described as a frontoparietal syndrome. 
 
Contribution of investigations 
 
Routine bloods, microbiology and basic antibodies provide no further diagnostic information. 
Imaging shows no significant white matter disease, mitigating against a vascular or conventional 
(eg, demyelinating) inflammatory process. Diffusion imaging provides no support for recent 
stroke or prion disease. There is atrophy affecting the posterior frontal lobe and the anterior 
parietal lobes but not the hippocampi, and there is progression (atrophy) between the studies. 
This is an unusual pattern, and would not be typical for the frontotemporal dementia (FTD) 
syndromes, or Alzheimer’s disease (AD). There is a hint of midbrain and cerebellar atrophy, 
which might suggest an atypical parkinsonian syndrome (progressive supranuclear palsy or 
multiple system atrophy) but the history would be atypical for either, and the dopamine 
transporter (DAT) scan is negative. 
 
He has two CSF examinations, both abnormal, with a mildly elevated cell count and unpaired 
oligoclonal bands on each occasion. He has had various negative genetic tests. Serum voltage-
gated potassium channel complex antibodies were negative; we would now test for specific 
antibody subtypes, but this syndrome does not fit with LGI-1 or CASPR2 antibody-associated 
encephalitis. Stiff-person syndrome is worth considering, but anti-glutamic acid decarboxylase 
antibodies are negative; antiglycine antibodies were presumably not available for testing at the 
time. Antineuronal antibodies were negative, although that a limited panel was reported. 
Further CSF studies included concentrations of tau and Aβ1–42. Tau is elevated in AD and often 
extremely elevated in prion disease, but was normal in this case. While a normal range for Aβ1–
42 is not provided, the assay usually employed in the UK has a normal range of ~550–650 pM/L, 
lower concentrations being abnormal. An Aβ1–42 of 104 in this case is very low, and perhaps 
more reflective of a handling/storage error than indicating brain β-amyloid deposition alone; in 
any case, the profile does not suggest AD. For the purposes of a CPC, it is important that 
Whipple’s PCR was negative. The sensitivity and specificity of the real-time quaking-induced 
conversion (RT-QuIC) test is extremely high for prion disease (4), and the normal concentration 
in this case strongly mitigates against this diagnosis, and sporadic Creutzfeldt-Jakob disease in 
particular. 
 
CT scans of chest, abdomen and pelvis were normal, reducing the likelihood of an occult tumour 
causing a paraneoplastic process, or sarcoidosis. The electroencephalogram was non-specific. 
The normal colonoscopy and endoscopy reinforce the clinical impression that his gastrointestinal 
symptoms are likely autonomic. 
 
Several investigations have not been performed: there is no MR scan of spinal cord, and no 
contrast MR scan of brain. Whole-body fluorodeoxyglucose-positron emission tomography, 
sensitive for detecting occult neoplasia, was not performed. There is no peripheral 
electrophysiology. Importantly, and as sleep impairment is such a dominant part of his 
presentation, the information from the sleep study is limited. He had 55 apnoeas and hypopnoeas 
per hour, putting him in the very severe category for sleep apnoea (severe >30 per hour). We do 
not know if he had rapid eye movement (REM) sleep behavioural disturbance which is seen in 
Lewy body diseases, but also in some autoimmune syndromes. We do not know if there is 
agrypnia excitata (complete loss of slow wave sleep with sustained autonomic activity), which 
limits the differential diagnosis to only a few conditions, such as Morvan’s syndrome, fatal 
familial insomnia or delirium tremens. 
 
In conclusion 
 
He is a 63-year-old man, with a 3-year history of a progressive fatal illness. Relevant findings are 
of early and prominent daytime somnolence, cognitive impairment with dysexecutive and 
parietal features, and gait disturbance. There is evidence for cerebellar or brainstem/cerebellar 
disconnection syndrome, with autonomic features. There is non-specific brain atrophy and an 
active CSF. The softer symptoms and signs include hints of an extrapyramidal disorder without 
parkinsonism, itch and weight loss. There was no response to modest immune suppression. 
 
Refining the diagnosis 
 
When faced with a difficult case, it is useful to go back to first principles and apply a ‘surgical 
sieve’ (Box 2). There is no evidence for a primary brain tumour but this does not exclude other 
malignancies, for example, intravascular lymphoma. A paraneoplastic syndrome cannot be 
excluded on current evidence but the history is relatively long. There are no ‘classical’ 
paraneoplastic antibodies, the caveat being that antibody testing and whole-body imaging were 
limited. His trip to India notwithstanding, there is no evidence for infection, for which the history 
would be long; imaging, HIV and treponemal serology were normal or negative. There are strong 
hints towards an immune process with an elevated CSF cell count and multiple central nervous 
system-specific bands. He did not respond to immunosuppression, although this was only a 
modest attempt, and not all autoimmune or inflammatory conditions respond to treatment. 
Degenerative causes are possible, with some soft signs suggestive of atypical parkinsonism, 
although the clinical features do not fit easily with any one of the classical syndromes, and the 
DAT scan was normal. Prion disease would, I think, be unlikely with the normal diffusion-
weighted MRI, negative RT-QuIC and active CSF. I think that trauma, metabolic and endocrine 
causes can safely be excluded.  
 
 
Box 2  
The surgical sieve with possible 
causes highlighted 
 Tumour/paraneoplastic 
 Trauma 
 Infection 
 Infarction 
 Immunological 
 Metabolic 
 Endocrine 
 Degenerative (including 
genetic) 
 Haematological 
 
 
 
There are two central features that one has to explain to solve this case: the profound 
somnolence and the active CSF. 
 
Many causes of somnolence can be excluded from the history, for example, narcolepsy, 
obstructive sleep apnoea, central hypoventilation and restless legs syndrome. There are several 
congenital syndromes with profound somnolence (Kleine-Levin, Prader-Willi, Coffin-Lowry), 
which clearly are not relevant. There were no hypothalamic lesions on the (unenhanced) 
imaging; some causes (eg, lymphoma) may not be seen. Degenerative causes such as Niemann-
Pick disease type C can give rise to somnolence with eye movement abnormalities and cerebellar 
dysfunction, but there is no splenomegaly and the active CSF would not fit. Conventional 
neurodegenerative disorders (AD, FTD and the parkinsonian syndromes) and prion disease, all of 
which can cause sleep impairment, are I think excluded. Sarcoidosis would be unusual without 
white matter imaging changes. Paraneoplastic and autoimmune conditions associated with 
CASPR2 and LGI-1 can cause REM sleep behaviour disorder and agrypnia. N-methyl-D-
aspartate antibodies were not done on the CSF but were negative in the serum. Aquaporin-4 
antibodies have been detected in narcolepsy but the history does not fit, and there are no 
imaging changes to suggest this diagnosis. Bickerstaff’s encephalitis can be associated with sleep 
disturbance; we do not know whether anti-GQ1b antibodies were present, but this would be a 
very long and indolent history. Finally, there is IgLON5 antibody syndrome, a relatively new 
autoimmune condition associated with prominent sleep disturbance. 
 
Of the above conditions, only a few would usually be associated with an active CSF: illnesses 
associated with hypothalamic invasion potentially could, as could paraneoplasia, sarcoidosis and 
the autoimmune conditions. Narrowing down the differential to the three most likely conditions 
on this basis leads me to suggest paraneoplasia, lymphoma and IgLON5. Table 1 provides 
information on these conditions and their associations with the core clinical features in this case. 
 
 Paraneoplastic Lymphoma IgLON5 
Somnolence +/- +/- ++ 
Cognitive + + + 
Gait +/- +/- ++ 
Cerebellar ++ +/- + 
Autonomic + + ++ 
Normal imaging +/- +/- ++ 
Cellular CSF + + +/- 
OCBs +/- +/- +/- 
 
Table 2, Clinical features present in the patient, and the frequency with which they are observed 
in paraneoplastic conditions, lymphoma and IgLON5 cases 
 
 
Conclusion and final diagnosis 
 
I think the best fit would be an IgLON5 antibody syndrome. The first case series of patients with 
IgLON5 antibodies was described a few years ago from a sleep laboratory, and several cases have 
since been described, with two larger case series published recently (5, 6).  IgLON5 is a neuronal 
cell adhesion molecule of unknown function. Honorat et al described 20 cases, with a median 
onset of 62 years, with insidious onset of sleep-disordered breathing and parasomnia, gait 
instability, abnormal eye movements, dysphagia, respiratory dysfunction, ataxia, dystonia, 
dysarthria, cognitive dysfunction, dysautonomia (bladder function, gut motility, 
thermoregulation, orthostatic intolerance) and normal MR scan of brain. In contrast to this case, 
the CSF was typically non-inflammatory, but was in some. The second case series from the Mayo 
Clinic reported 22 patients, median onset 64 years of age, where the initial problem was with 
sleep in one-third, gait problems in a further third, bulbar dysfunction in 14%, chorea in 9% and 
cognitive decline in 5%. They describe four subtypes: a sleep disorder with parasomnia and sleep 
breathing difficulty; a bulbar syndrome; a progressive supranuclear palsy-like syndrome; and a 
syndrome associated with cognitive decline with or without chorea. All developed parasomnia, 
sleep apnoea, insomnia or excess sleepiness, and there was a strong association with HLA-
DRB1*10 001 and HLA-DQB1*0501. The cases had often been diagnosed as atypical multiple 
system atrophy or atypical progressive supranuclear palsy. IgLON5 cases also have an intriguing 
link between autoimmunity and neurodegeneration, with the pathology showing three-
repeat (3R) and four-repeat (4R) tau, without evidence of inflammation, in the basal ganglia, the 
hypothalamus and other regions accounting for the specific symptoms, and there are now 
pathological criteria described. 
While I have never diagnosed a case previously and so do so with trepidation, my suggestion is 
that the patient had anti-IgLON5 disease, and that pathology will show subcortical deposition of 
3R and 4R tau. 
 
 
Questions from the audience (part 1) 
 
Jon Stone [JXXXS]: He was my patient and neighbour of my sister in law, so I knew him before he 
became unwell. His family commented that previously he was a chronic insomniac, so 
hypersomnia was a significant change. 
 
Suvankar Pal [SP]: He passed through my memory clinic. I remember feeling anxious about his 
CSF cell count, and it was about this time that he had the treatment with steroids. 
JS: Did you consider more intensive immune suppression? 
 
JXXXS: He deteriorated so rapidly that we agreed with the family it was not worthwhile pursuing. 
JS: If it were IgLON5, the evidence seems to be that patients do not typically respond to immuno-
suppression in any case. 
 
Audience member: With the profound weight loss, gastrointestinal symptoms, do you think anti-
DPPX (anti dipeptidyl-peptidase-like protein 6) syndrome might be a possibility? 
 
JS: I have not seen a case of DPPX antibody-associated encephalitis but the typical triad is of 
cognitive decline, diarrhoea and gastro-intestinal disturbance and central nervous system hyper-
excitability rather than sleepiness. Having seen how the phenotype of new autoimmune 
conditions can expand over time, I would however not exclude this as a possibility. 
 
Alison Green [AG]: Do you know if there are reports of CSF phosphorylated tau being elevated in 
IgLON5? 
 
JS: We know that CSF tau is often not elevated in a number of primary tauopathies (eg, 
progressive supranuclear palsy), but I do not know if this has been established in IgLON5. 
 
AG: We found that of the CSF samples of patients with Creutzfeldt-Jakob disease, 1% are 
associated with moderately elevated white cell counts, such as 7 or so. Once you get to 20 white 
cells then it becomes very unlikely. 
 
Pathology 
 
The brain was within normal limits, weighing 1364 g. The cerebrum showed no obvious atrophy, 
and on sectioning there were no macroscopic focal lesions in cortical grey matter, white matter 
or deep grey matter. The main pathology was related to the cerebellum, which showed striking 
atrophy, predominantly involving the vermis and the medial parts of the hemispheres bilaterally. 
Histological assessment of brain sections confirmed cerebellar pathology. Within the cerebellar 
cortex there were areas of clear damage, with degenerating Purkinje cells and torpedoes 
(fusiform swellings of Purkinje cell axons within the granular layer). The initial 
immunohistochemical assessment of proteins associated with neurodegeneration was 
undertaken, assessing tau, β-amyloid and α-synuclein. 
 
There were occasional neurofibrillary tangles identified by tau immunohistochemistry but 
limited to the entorhinal cortex, with a few β-amyloid immunoreactive diffuse plaques. Further 
immunohistochemistry showed no deposition of abnormal prion protein, TDP43, ubiquitin or 
fused in sarcoma (FUS). 
 
At this stage the pathological conclusions were as follows: 
 Focal cerebellar atrophy. 
 Tau pathology Braak stage 1. 
 β-amyloid plaque Thal phase 1. 
  
In addition, there was no inflammation excluding an encephalitic process, and no evidence of any 
neoplastic process. From a prion perspective, he was part of a study that included detailed 
biochemical and histochemical assessment, and this was negative. 
 
When considering a neurodegenerative disorder, we go through the following processes. We 
assess extracellular and intracellular abnormal protein accumulation. Extracellular accumulation 
is mainly amyloid, with parenchymal and vascular forms, and with this we may see an associated 
vasculitis. We then move through the intracellular proteins that can accumulate including 
tauopathies, synucleinopathies, TDP-43 proteinopathies, FUS and polyQ (trinucleotide repeat) 
disorders. The mix of proteins and the pattern of protein distribution (neuronal, glial, mixed) 
helps determine the more precise pathological diagnosis. 
 
Pathologists use the same diagnostic process as clinicians; starting with a wide range of 
differentials suggested by the clinical presentation aligned with histopathological and 
immunohistochemical assessment, until we arrive at a final diagnosis. Thus, in this case, the 
important negatives are: there was no neoplastic process, including gliomatosis, and no 
intravascular lymphoma; there was no metabolic encephalitic process, and no inflammatory 
processes, including those described for paraneoplastic conditions. We then consider 
neurodegenerative conditions. With regard to extracellular protein deposition we have excluded 
a prionopathy, and we have no evidence of any amyloid disorders, such as β-amyloid deposition 
or the rare familial amyloidoses. We then consider intracellular proteinopathies; there was no 
glial tau deposition and very limited neuronal expression of tau. There was no tau deposition in 
the hypothalamus or tegmentum of the brainstem as has previously been described in IgLON5 
cases. There was no abnormal deposition of α-synuclein, TDP-43, FUS, and no evidence of 
neuroserpin disorders or neuroferritinopathies. We did see polyglutamine accumulation in the 
vermis in the Purkinje cells. However, it is not the typical distribution one would expect for a 
trinucleotide repeat disorder, where nuclear accumulation is typically described. Cytoplasmic 
accumulation is described but not in the absence of a nuclear component. There was also no 
colocalisation with ubiquitin, which is typical of trinucleotide repeat disorders. However, the 
polyQ accumulation was considered to be pathological deposition in the cytoplasm of Purkinje 
cells, and minimal amounts in cortical neurones. Given the clinical scenario, I wondered about 
SCA17. There is a single postmortem report that describes polyQ accumulation although it was 
predominantly nuclear. 
 
The bottom line, following detailed postmortem examination, is we do not have a definitive 
pathological diagnosis. 
 
Questions and comments from the (stunned and now silent) audience (part 2) 
 
RJD: You’re thinking why on earth choose this for a CPC—a case with no answer? Well this is real 
life, we wondered if more analysis during a CPC might lead to a diagnosis. We now have a clinical 
diagnosis and a pathological diagnosis (sort of), which are different. 
 
JS: Given the extent of the symptoms and signs, the absence of much in the way of 
neuropathological findings and of a definite diagnosis is surprising. What little there is to go on 
suggests cerebellar pathology. The possibility of SCA-17 was raised—this is typically considered 
as a differential diagnosis of Huntington’s disease, and whilst it can be associated with a broader 
and variable clinical phenotype, I do not think this would easily explain some of the allied details, 
such as active CSF, and prominent drowsiness. 
 
JXXXS: It’s disappointing you didn’t find [pathological] atrophy, to match with the MRI scans. 
What were we looking at with the MRI? He also appeared to have parietal signs, so are we just 
appearing to see what we want to see? I’m assuming that pathology is the gold standard. 
Colin Smith: I think it’s the resolution of the naked eye looking at brain sections as opposed to the 
resolution of MRI, especially where you can look at things sequentially. Certainly though, the 
brain weight was within normal limits, and the atrophy cannot have been terribly significant if 
not present to the naked eye. 
 
Further testing 
 
Post-CPC testing for IgLON5 antibodies and SCA17 genetics were negative. Rather than wrapping 
this case up with a neat final diagnosis, this allows us to highlight a number of learning points. 
A precise diagnosis can elude highly experienced neurologists, even with the assistance of 
postmortem data. The patient had a rich array of symptoms to help localisation and diagnosis. 
Some of these signs had their own difficulties in interpretation though, such as appearing 
superficially parkinsonian, but without parkinsonism. The case highlighted how fresh eyes can 
also uncover new possibilities: SCA-17 and IgLON5 were not considered before this CPC. Partly 
this is because for IgLON5 the antibody and syndrome were only characterised in 2014 (7).  
Professor Schott discussed the fast-evolving world of antibodies associated with autoimmune 
and paraneoplastic encephalopathies. Surrogate markers such as thyroid peroxidase or 
intracellular targets such as Ri, Yo and Hu are giving way to more specific antigenic targets. The 
field has evolved through the refinement of voltage-gated potassium channel complex antibodies 
to CASPR2 and LGI-1, to an explosion of overlapping syndromes associated with cell surface 
antibodies against GABA-A, GABA-B, glycine, AMPA, mGluR5, mGluR1, Homer-3, DNER and DPPX, 
to name a few (8). It would be naïve to believe there are no further syndromes and antibodies 
awaiting identification. Similarly, the molecular and genetic basis of neurodegeneration 
continues to expand, for example, the spinocerebellar ataxias. In addition, the testing for these 
conditions advances, as single gene testing moves towards panels, and inevitably with time 
towards whole exome and genome sequencing. 
 
This case demonstrated an expert’s way of working to refine the diagnosis, which is the true 
value of a CPC, the ultimate teaching resource. Professor Schott approached the case from several 
angles. He focused on the history to identify the cause and to localise the problems. His focus on 
the extensive investigation results was to identify the few key results. This working enabled him 
to hone in on three key possibilities: two autoimmune processes (paraneoplasia and IgLON5) or 
lymphoma. The pathology excluded lymphoma, but what of the two autoimmune processes? 
Paraneoplastic conditions are associated with a wide array of pathology depending on the 
underlying condition. Paraneoplastic cerebellar degeneration (PCD) is the most common central 
paraneoplastic syndrome. Even among cases of PCD though there is heterogeneity in terms of 
location of damage, but also pathological changes. Some cases are purely degenerative, with loss 
of Purkinje and basket cells, and thinning of the molecular layer. In these cases, the deep grey 
nuclei are spared. Some patients with PCD have inflammatory changes, with reactive astrocytes 
and inflammation of the overlying leptomeninges (9).  Some patients with PCD have cell loss 
within the corticospinal, spinocerebellar and dorsal column tracts, whereas in others it is 
confined to the cerebellum. Whether this heterogeneity is related to the associated antibody is 
unknown: PCD has been found associated with Yo, Hu, Ri, P/Q-voltage-gated calcium channel, 
CRMP5, Ma and Zic4 antibodies (8).  The lack of a whole-body postmortem means that a distant 
malignancy cannot be excluded. 
 
There are proposed pathological criteria for IgLON5 disease (10).  The brains of six patients were 
examined and found to have very similar neurodegenerative features with accumulation of 3R 
and 4R tau in a rostrocaudal gradient of severity. The areas with highest density were the 
hypothalamus, brainstem tegmentum, pons and medulla. The distribution of tau mimics that of 
progressive supranuclear palsy, but is absent from the basal ganglia and supratentorial regions. 
In addition to the characteristic neurodegeneration, IgLON5 disease is also associated with HLA-
DRB1*1001 and HLA-DQB1*0501 haplotypes in all tested cases. Postmortem antibody testing 
appears to have excluded this diagnosis, although which autoimmune disorder does not include 
an ‘antibody-negative’ subsection? 
 
It is unusual and unexpected to have CPC without a pathological diagnosis. It is difficult to know 
the prevalence of progressive, fatal neurological disorders with unenlightening postmortem 
pathology. However, there are case series of brain biopsies in the diagnosis of various 
neurodegenerative and inflammatory conditions. Warren et al (11) performed a retrospective 
analysis of 90 biopsies taken to investigate of dementia between 1989 and 2003 at the National 
Hospital for Neurology and Neurosurgery, London, UK. This was predominantly in younger cases 
where there was felt to be the possibility of a reversible cause. One of these biopsies was 
reported as normal, and 33 showed non-specific gliosis. The biopsies were predominantly full 
thickness resections of leptomeninges, cortex and white matter from the non-dominant frontal 
lobe. Unfortunately, most of these cases were lost to follow-up subsequently but 10 patients in 
the study had postmortems. Six of these had non-specific biopsy findings, and postmortems were 
diagnosed as Creutzfeldt-Jakob disease (three cases), multiple sclerosis, cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leukoencephalopathy and, finally, suggestion 
of a mitochondrial cytopathy. Biopsy is much more likely to miss focal inflammatory or 
neurodegenerative pathology. If a patient with IgLON5 had a non-dominant frontal lobe biopsy it 
would be expected to appear either normal or non-diagnostic based on the six cases described 
(10).  The CPC discussant was the first author on a follow-up study to Warren et al’s biopsy study, 
looking at brain biopsies between 2004 and 2009 at the same institute. This identified 19 cases, 
and the biopsy was diagnostic in 74%. Of the non-diagnostic biopsies, four had non-specific 
gliosis or non-specific chronic inflammation, one extensive cortical necrosis and none were 
normal. 
 
This case has been educational into the role of generating a differential diagnosis, as well as an 
overview of IgLON5 disease and its associated pathology. However, the case still lacks a final 
diagnosis, and in the spirit of collaboration we open this up to readers for further suggestions. 
 
Key points 
 Prominent neurological symptoms and signs may not reflect structural abnormalities 
picked up either by imaging or by pathology. 
 Autopsy does not always provide the diagnosis. 
 There has been a recent explosion in the number of paraneoplastic antibody associated 
syndromes, but for most the pathological findings are unknown. 
 IgLON5 is a recently described paraneoplastic syndrome associated with prominent 
sleep disorder. 
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